Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Current Assets (2020 - 2025)

Maravai Lifesciences Holdings has reported Current Assets over the past 6 years, most recently at $296.3 million for Q4 2025.

  • Quarterly results put Current Assets at $296.3 million for Q4 2025, down 30.97% from a year ago — trailing twelve months through Dec 2025 was $296.3 million (down 30.97% YoY), and the annual figure for FY2025 was $296.3 million, down 30.97%.
  • Current Assets for Q4 2025 was $296.3 million at Maravai Lifesciences Holdings, down from $325.9 million in the prior quarter.
  • Over the last five years, Current Assets for MRVI hit a ceiling of $847.9 million in Q4 2022 and a floor of $296.3 million in Q4 2025.
  • Median Current Assets over the past 5 years was $680.3 million (2024), compared with a mean of $612.0 million.
  • Biggest five-year swings in Current Assets: skyrocketed 123.17% in 2021 and later crashed 52.02% in 2025.
  • Maravai Lifesciences Holdings' Current Assets stood at $740.0 million in 2021, then grew by 14.58% to $847.9 million in 2022, then dropped by 17.45% to $699.9 million in 2023, then tumbled by 38.69% to $429.1 million in 2024, then tumbled by 30.97% to $296.3 million in 2025.
  • The last three reported values for Current Assets were $296.3 million (Q4 2025), $325.9 million (Q3 2025), and $359.8 million (Q2 2025) per Business Quant data.